Moreover, the anti‐NAFLD effect of ezetimibe, as evidenced by the complete prevention and rescue of steatosis, together with the potential medicinal property of the TLR4 antagonist, could contribute to the development of new therapeutic strategies for this global health problem. The gene discussed is TLR4; the disease is metabolic dysfunction-associated steatotic liver disease.